Summary
The influence of age on amikacin pharmacokinetics was examined in 87 patients with normal renal function. All patients had a gram negative infection, were febrile, weighed within 20% of their ideal body weight, did not receive penicillin antibiotics concurrently, had normal hematocrits and had a measured 24 h creatinine clearance greater than 80 ml/min/1.73 m2. 31 patients were 20–39 years old, 27 patients were between the ages of 40–59 years, and 29 patients were 60–79 years old. These patients were compared to patients in similar previous studies who received gentamicin or tobramycin. No significant differences in clearance, volume of distribution or half-life were found due to age within a single drug group (amikacin, gentamicin, or tobramycin) or among the 3 drug groups. However, a substantial amount of intersubject variability existed in the calculated pharmacokinetic parameters. Patients over 40 years old tended to be underdosed with amikacin and the other 2 aminoglycosides. The average amikacin dose needed to achieve the desired steady-state concentrations was 18.9 mg/kg/day. 52% of the amikacin patients required doses greater than the recommended maximum (15 mg/kg/day). Since aminoglycoside pharmacokinetics do not change as age increases, doses do not need to be arbitrarily changed in older patients with normal renal function.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mawer GE, Ahmad R, Dobbs SM (1974) Prescribing aids for gentamicin. Br J Clin Pharmacol 1: 45–50
Dahlgren JG, Anderson ET, Hewitt WL (1975) Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 8: 58–62
Bauer LA, Blouin RA (1982) Gentamicin pharmacokinetics: Effect of aging in patients with normal renal function. J Am Geriatrics Soc 30: 309–11
Bauer LA, Blouin RA (1981) Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother 20: 587–9
Devine BJ (1974) Gentamicin therapy. Drug Intell Clin Pharm 8: 650–655
Sawchuk RJ, Zaske DE (1976) Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions. J Pharmacokinet Biopharm 4: 183–195
Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG (1977) Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 21: 362–369
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York
Cutler RE, Gyselynck AM, Fleet P, Forrey AW (1972) Correlation of serum creatinine concentration and gentamicin halflife. J Am Med Assoc 219: 1037–41
Barza M, Brown RB, Shen D, Gibaldi M, Weinstein L (1975) Predictability of blood levels of gentamicin in man. J Infect Dis 132: 165–174
Pennington JE, Dale DC, Reynolds HY (1975) Gentamicin sulfate pharmacokinetics: Lower levels of gentamicin during fever. J Infect Dis 132: 270–275
Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM (1980) Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 37: 517–522
Ervin FR, Bullock WE, Nuttall CE (1976) Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrob Agents Chemother 9: 1004–1011
Gault MH, Cockcroft DW (1975) Creatinine clearance and age. Lancet 2: 612–613
Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW (1976) The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 31: 155–163
Zaske DE, Irvine P, Strand LM, Strate RG, Cipolle RJ, Rotschafer J (1982) Wide interpatient variations in gentamicin dose requirements for geriatric patients. J Am Med Assoc 248: 3122–3126
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bauer, L.A., Blouin, R.A. Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 24, 639–642 (1983). https://doi.org/10.1007/BF00542214
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542214